Bb5a31f81ClaimAs of November 2026, the average development cost of a new drug has risen to approximately 1.5 billion dollarsAgreeDisagree
Bb5a31f81ClaimPreclinical toxicity studies conducted in rats are approximately 30 percent predictive of clinical toxicity in humansAgreeDisagree
Bb5a31f81ClaimMost candidate drugs fail during human clinical trials rather than during preclinical in-vitro researchAgreeDisagree
Bb5a31f81ClaimDeveloping a new drug traditionally takes approximately 15 years from initial discovery to regulatory approvalAgreeDisagree
Bb5a31f81ClaimPatients facing late-stage terminal cancers typically possess a higher tolerance for treatment risk than patients treated for chronic low-level inflammationAgreeDisagree
Bb5a31f81ClaimDespite an expansion in biomedical literature and drug modalities, the annual number of new drug approvals has remained roughly flatAgreeDisagree
Bb5a31f81ClaimIn-vitro laboratory endpoints can be combined with computational predictive models and synthetic human tissues to assess clinical toxicityAgreeDisagree
Bb5a31f81ClaimRevolution Medicines developed the KRAS inhibitor daraxonrasib to treat late-stage pancreatic cancer patientsAgreeDisagree
Bb5a31f81ClaimApproximately 10% of experimental drug candidates successfully pass clinical trialsAgreeDisagree
Bb5a31f81ClaimAntisense oligonucleotides are short RNA molecules designed to bind target RNA transcripts to modify splicing or gene expressionAgreeDisagree
Bb5a31f81ClaimGLP-1 receptor agonist medications suppress appetite by targeting neural signaling pathways that regulate hunger and body weight settling pointsAgreeDisagree
Bb5a31f81ClaimApproximately 50% to 60% of patients prescribed GLP-1 receptor agonist medications discontinue treatment within a few yearsAgreeDisagree
Bb5a31f81ClaimRapid weight loss from GLP-1 receptor agonists often includes substantial reductions in skeletal muscle mass alongside fat lossAgreeDisagree
Bb5a31f81ClaimMore than 20 pharmaceutical companies reached agreements with the Trump administration pledging not to charge significantly higher drug prices in the United States than in other nationsAgreeDisagree
Bb5a31f81ClaimBayer co-markets a blood-thinner medication with Johnson & Johnson that faces generic market competitionAgreeDisagree
Bb5a31f81ClaimA randomized controlled trial investigating the African heritage diet examined the health effects of consuming 90 grams of fiber per dayAgreeDisagree
Bb5a31f81ClaimPharmaceutical companies pulled drugs or delayed launches in European markets to avoid lowering domestic United States drug prices under reference-pricing dealsAgreeDisagree
Bb5a31f81ClaimBayer's drug San Arbo is designed to prevent repeat strokes without significantly increasing a patient's bleeding risk compared to standard blood thinnersAgreeDisagree
Bb5a31f81ClaimThe United States Food and Drug Administration approved Bayer's blood thinner San Arbo to decrease the risk of dangerous internal bleedingAgreeDisagree
Bb5a31f81ClaimMarket research firm GlobalData recorded a 27% decline in new European pharmaceutical launches over a 17-month periodAgreeDisagree